Mylan Challenge To “Authorized” Generics May Shift To Antitrust Arguments

Mylan could turn to antitrust laws as an avenue for renewing a court challenge against "authorized" generics after dropping its lawsuit against FDA

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet